In an analyst note published on Wednesday, Goldman Sachs predicted that the virtual reality (VR) market will outpace the TV market in annual revenue by 2025, making VR bigger than TV.
The banking firm writes that the VR market will generate $110 billion dollars compared to TVs $99 billion in 10 years.
This will happen if VR adoption follows their “Accelerated Uptake” projection, in which virtual reality becomes more commonplace through advances in battery and cellular technologies. By eventually ditching the current wires and accompanying computers needed to power high-end VR headsets, the devices would become truly mobile; think a headset that’s more akin to a pair of sunglasses than the bulky goggles of the first generation Oculus Rift and HTC Vive.



Last week at CES, South San Francisco based Profusa showed off an upcoming injectable sensor that can be used to continuously monitor oxygen levels in tissue. Measuring only five millimeters long and a tiny 250 microns in diameter, the biosensor can be injected into tissue with just a hypodermic needle. It consists of a soft hydrogel scaffold that allows it to be biologically compatible with the surrounding tissue without any foreign body response. The sensor also contains a special chemical marker that changes fluorescence depending on the amount of oxygen that reacts with it. An optical reader placed on the skin measures the fluorescence and relays the data to a smartphone. The biosensor can last as long as two years (at which point the chemical marker begins to lose its potency), and because it contains no electronics and is completely biocompatible there’s no need to remove it.


